AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion
AbbVie on Wednesday said it will acquire neuroscience drugmaker Cerevel Therapeutics for roughly $8.7 billion. Under the terms of the deal, AbbVie will pay $45 per share for…
Read more AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion